Sitravatinib With or Without Tislelizumab in Patients With Unresectable or Metastatic Melanoma
Clinical trial NCT05104801 · UNKNOWN
Trial details
- NCT number
- NCT05104801
- Sponsor
- Peking University Cancer Hospital & Institute
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-01
- Primary completion
- 2023-09-01
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.